FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378746710> ?p ?o ?g. }

• W4378746710 endingPage "732" @default.
• W4378746710 startingPage "732" @default.
• W4378746710 abstract "Importance Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysis based on evidence from randomized comparisons to alteplase as well as for its practical advantages. There have been no significant differences in symptomatic intracranial hemorrhage (sICH) reported from randomized clinical trials or published case series for the 0.25-mg/Kg dose. Objective To assess the risk of sICH following ischemic stroke in patients treated with tenecteplase compared to those treated with alteplase. Design, Setting, and Participants This was a retrospective observational study using data from the large multicenter international Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) collaboration comprising deidentified data on patients with ischemic stroke treated with intravenous thrombolysis. Data from more than 100 hospitals in New Zealand, Australia, and the US that used alteplase or tenecteplase for patients treated between July 1, 2018, and June 30, 2021, were included for analysis. Participating centers included a mix of nonthrombectomy- and thrombectomy-capacity comprehensive stroke centers. Standardized data were abstracted and harmonized from local or regional clinical registries. Consecutive patients with acute ischemic stroke who were considered eligible and received thrombolysis at the participating stroke registries during the study period were included. All 9238 patients who received thrombolysis were included in this retrospective analysis. Main Outcomes and Measures sICH was defined as clinical worsening of at least 4 points on the National Institutes of Health Stroke Scale (NIHSS), attributed to parenchymal hematoma, subarachnoid, or intraventricular hemorrhage. Differences between tenecteplase and alteplase in the risk of sICH were assessed using logistic regression, adjusted for age, sex, NIHSS score, and thrombectomy. Results Of the 9238 patients included in the analysis, the median (IQR) age was 71 (59-80) years, and 4449 patients (48%) were female. Tenecteplase was administered to 1925 patients. The tenecteplase group was older (median [IQR], 73 [61-81] years vs 70 [58-80] years; P &amp;lt; .001), more likely to be male (1034 of 7313 [54%] vs 3755 of 1925 [51%]; P &amp;lt; .01), had higher NIHSS scores (median [IQR], 9 [5-17] vs 7 [4-14]; P &amp;lt; .001), and more frequently underwent endovascular thrombectomy (38% vs 20%; P &amp;lt; .001). The proportion of patients with sICH was 1.8% for tenecteplase and 3.6% for alteplase ( P &amp;lt; .001), with an adjusted odds ratio (aOR) of 0.42 (95% CI, 0.30-0.58; P &amp;lt; .01). Similar results were observed in both thrombectomy and nonthrombectomy subgroups. Conclusions and Relevance In this large study, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than treatment with alteplase. The results provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clinical practice." @default.
• W4378746710 created "2023-05-31" @default.
• W4378746710 creator A5007914001 @default.
• W4378746710 creator A5012455480 @default.
• W4378746710 creator A5013636176 @default.
• W4378746710 creator A5013736649 @default.
• W4378746710 creator A5018771705 @default.
• W4378746710 creator A5020896168 @default.
• W4378746710 creator A5021832203 @default.
• W4378746710 creator A5023101211 @default.
• W4378746710 creator A5023160611 @default.
• W4378746710 creator A5024100883 @default.
• W4378746710 creator A5025708661 @default.
• W4378746710 creator A5027780282 @default.
• W4378746710 creator A5029041310 @default.
• W4378746710 creator A5031563288 @default.
• W4378746710 creator A5034143823 @default.
• W4378746710 creator A5039090799 @default.
• W4378746710 creator A5049315425 @default.
• W4378746710 creator A5052798040 @default.
• W4378746710 creator A5052800925 @default.
• W4378746710 creator A5058260799 @default.
• W4378746710 creator A5059244344 @default.
• W4378746710 creator A5062380972 @default.
• W4378746710 creator A5062808534 @default.
• W4378746710 creator A5066091053 @default.
• W4378746710 creator A5067472323 @default.
• W4378746710 creator A5067940704 @default.
• W4378746710 creator A5069705836 @default.
• W4378746710 creator A5069989341 @default.
• W4378746710 creator A5073043953 @default.
• W4378746710 creator A5074508324 @default.
• W4378746710 creator A5077020556 @default.
• W4378746710 creator A5083101662 @default.
• W4378746710 creator A5085964893 @default.
• W4378746710 creator A5089564885 @default.
• W4378746710 creator A5090256845 @default.
• W4378746710 date "2023-07-01" @default.
• W4378746710 modified "2023-10-13" @default.
• W4378746710 title "Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke" @default.
• W4378746710 cites W1900208830 @default.
• W4378746710 cites W1972869299 @default.
• W4378746710 cites W2021754784 @default.
• W4378746710 cites W2086781038 @default.
• W4378746710 cites W2096711488 @default.
• W4378746710 cites W2111255873 @default.
• W4378746710 cites W2156845192 @default.
• W4378746710 cites W2165568749 @default.
• W4378746710 cites W216595465 @default.
• W4378746710 cites W2740053016 @default.
• W4378746710 cites W2802880180 @default.
• W4378746710 cites W2886777603 @default.
• W4378746710 cites W2905585525 @default.
• W4378746710 cites W2965350298 @default.
• W4378746710 cites W2982303713 @default.
• W4378746710 cites W3042465754 @default.
• W4378746710 cites W3130625382 @default.
• W4378746710 cites W3132060044 @default.
• W4378746710 cites W3194455757 @default.
• W4378746710 cites W3197516697 @default.
• W4378746710 cites W3205262398 @default.
• W4378746710 cites W3208279890 @default.
• W4378746710 cites W3217495045 @default.
• W4378746710 cites W4229056829 @default.
• W4378746710 cites W4229363911 @default.
• W4378746710 cites W4283798291 @default.
• W4378746710 cites W4296794280 @default.
• W4378746710 cites W4319663675 @default.
• W4378746710 doi "https://doi.org/10.1001/jamaneurol.2023.1449" @default.
• W4378746710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37252708" @default.
• W4378746710 hasPublicationYear "2023" @default.
• W4378746710 type Work @default.
• W4378746710 citedByCount "3" @default.
• W4378746710 countsByYear W43787467102023 @default.
• W4378746710 crossrefType "journal-article" @default.
• W4378746710 hasAuthorship W4378746710A5007914001 @default.
• W4378746710 hasAuthorship W4378746710A5012455480 @default.
• W4378746710 hasAuthorship W4378746710A5013636176 @default.
• W4378746710 hasAuthorship W4378746710A5013736649 @default.
• W4378746710 hasAuthorship W4378746710A5018771705 @default.
• W4378746710 hasAuthorship W4378746710A5020896168 @default.
• W4378746710 hasAuthorship W4378746710A5021832203 @default.
• W4378746710 hasAuthorship W4378746710A5023101211 @default.
• W4378746710 hasAuthorship W4378746710A5023160611 @default.
• W4378746710 hasAuthorship W4378746710A5024100883 @default.
• W4378746710 hasAuthorship W4378746710A5025708661 @default.
• W4378746710 hasAuthorship W4378746710A5027780282 @default.
• W4378746710 hasAuthorship W4378746710A5029041310 @default.
• W4378746710 hasAuthorship W4378746710A5031563288 @default.
• W4378746710 hasAuthorship W4378746710A5034143823 @default.
• W4378746710 hasAuthorship W4378746710A5039090799 @default.
• W4378746710 hasAuthorship W4378746710A5049315425 @default.
• W4378746710 hasAuthorship W4378746710A5052798040 @default.
• W4378746710 hasAuthorship W4378746710A5052800925 @default.
• W4378746710 hasAuthorship W4378746710A5058260799 @default.
• W4378746710 hasAuthorship W4378746710A5059244344 @default.
• W4378746710 hasAuthorship W4378746710A5062380972 @default.
• W4378746710 hasAuthorship W4378746710A5062808534 @default.

• next